Using transcriptomic data for patients with NSCLC (n = 439) from two randomized clinical trial cohorts treated with a single anti-PD-L1 antibody (atezolizumab), we provide evidence for the association of TRNs with therapy failure. The gene discussed is CD274; the disease is non-small cell lung carcinoma.